AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance
Description: 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression
Description: 8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84
Study NCT02532543 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alloplast, Membrane
Description: Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
Study NCT02532543 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft, Membrane
Description: Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
Study NCT02532543 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Membrane
Description: Membrane - Symbios OsteoShield Collagen Resorbable Membrane
Study NCT03524872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Original CAD/CAM prosthetic abutment
Description: Original (Sweden\&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.
Study NCT03524872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compatible CAD/CAM abutment
Description: Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.
Study NCT01410227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF)
Description: Intravenous administration
Study NCT01410227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Syringe supplied with physiologic saline solution for infusion
Study NCT01410227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIII (rFVIII)
Description: Intravenous administration
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression
Description: 8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function
Description: 8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function
Description: 8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
Study NCT05421403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenotonsillectomy
Description: all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade >2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated
Study NCT05421403 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle intervention
Description: After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of \~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Center for Epidemiological Studies - Depression
Description: 20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Center for Epidemiological Studies - Depression
Description: 20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Description: The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Cognitive Assessment (MoCA)
Description: The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)
Description: The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)
Description: The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Log
Description: -A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue \& sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
Study NCT03304587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Log
Description: -A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue \& sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
Study NCT03524872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Description: Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).
Study NCT03524872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia
Description: Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).
Study NCT03524872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Painkillers
Description: Patients will be prescribed ibuprofen 600 mg three times per day for five days
Study NCT03524872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Painkillers
Description: Patients will be prescribed ibuprofen 600 mg three times per day for five days
Study NCT03524872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwashes
Description: Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
Study NCT02972762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan
Description: anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
Study NCT03444987 — intervention group
Intervention type: GENETIC
Intervention: Measurement of protein expression in tissues.
Description: The followings markers will be estimated in tissue~1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~5. Reduced glutathione, an antioxidant marker by a colorimetric method
Study NCT04380636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous (IV) infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: oral tablets
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for olaparib
Description: oral tablets
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: IV infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT01976611 — intervention group
Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
Study NCT01924403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staple Closure
Study NCT04380636 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Radiotherapy
Description: external beam radiation
Study NCT04380636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: external beam radiation
Study NCT04380636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: IV infusion
Study NCT03256656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials
Study NCT03256656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials
Study NCT04635670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pro-/prebiotic Mix
Description: Soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
Study NCT00776763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin intravitreal injection
Description: 1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
Study NCT01429363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted disc decompression
Description: The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
Study NCT04865003 — intervention group
Intervention type: OTHER
Intervention: treatment of infection
Study NCT01983501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib (ONT-380)
Description: Given twice per day, orally
Study NCT01983501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Given intravenously once every 21 days
Study NCT03151577 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: XEN® Gel Stent implantation
Description: Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
Study NCT05606458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: İntervention Group
Description: Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
Study NCT01022983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
Study NCT01022983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levosimendan
Description: At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
Study NCT01022983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ml/kg/hours - same infusion rate as active comparator
Study NCT01496495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-614, p38/Tie2 inhibitor; oral
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
Study NCT02922569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
Study NCT02922569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Thirty minutes of training on computerized, casual video games.
Study NCT02922569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
Study NCT02922569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traumatic Brain Injury Information Session
Description: Ten minutes of viewing traumatic brain injury related news, information, and programs.
Study NCT02121067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Intrauterine System (LNG-IUS)
Description: The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
Study NCT03524872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwashes
Description: Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
Study NCT03524872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Dental implants (Sweden \& Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
Study NCT03524872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Dental implants (Sweden \& Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
Study NCT03976232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans cranial Direct Current Stimulation (tDCS)
Description: Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.
Study NCT03976232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (CST)
Description: Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.
Study NCT03976232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS+ CST
Description: This group will receive tDCS along with CST
Study NCT02120586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT).
Description: Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10.